Atrium Therapeutics, Inc. Common Stock
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treat… Read more
Atrium Therapeutics, Inc. Common Stock (RNA) - Net Assets
Latest net assets as of December 2025: $1.69 Billion USD
Based on the latest financial reports, Atrium Therapeutics, Inc. Common Stock (RNA) has net assets worth $1.69 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.96 Billion) and total liabilities ($269.45 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.69 Billion |
| % of Total Assets | 86.24% |
| Annual Growth Rate | 55.76% |
| 5-Year Change | 342.7% |
| 10-Year Change | 8122.63% |
| Growth Volatility | 195.23 |
Atrium Therapeutics, Inc. Common Stock - Net Assets Trend (2011–2025)
This chart illustrates how Atrium Therapeutics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Atrium Therapeutics, Inc. Common Stock (2011–2025)
The table below shows the annual net assets of Atrium Therapeutics, Inc. Common Stock from 2011 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.69 Billion | +18.50% |
| 2024-12-31 | $1.42 Billion | +184.56% |
| 2023-12-31 | $500.76 Million | -13.37% |
| 2022-12-31 | $578.08 Million | +51.55% |
| 2021-12-31 | $381.43 Million | +24.56% |
| 2020-12-31 | $306.22 Million | +568.54% |
| 2019-12-31 | $-65.36 Million | -58.91% |
| 2018-12-31 | $-41.13 Million | -147.22% |
| 2013-12-31 | $87.10 Million | +324.12% |
| 2012-12-31 | $20.54 Million | +501.88% |
| 2011-12-31 | $3.41 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Atrium Therapeutics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 157769700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $15.00K | 0.00% |
| Other Comprehensive Income | $2.56 Million | 0.15% |
| Other Components | $3.26 Billion | 193.28% |
| Total Equity | $1.69 Billion | 100.00% |
Atrium Therapeutics, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Atrium Therapeutics, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AG MORTG.INV.NEW DL-01
F:8AGA
|
$207.28 Million |
|
Jasmine International Public Company Limited
PINK:JASUF
|
$207.30 Million |
|
Tianjin LVYIN Landscape and Ecology Construction Co Ltd
SHE:002887
|
$207.30 Million |
|
ABG Sundal Collier Holding ASA
PINK:ABGSF
|
$207.31 Million |
|
Shanghai Huaming Intelligent Terminal Equipment Co Ltd
SHE:300462
|
$207.27 Million |
|
Clearwater Paper Corporation
NYSE:CLW
|
$207.12 Million |
|
Advanced Ceramic X
TWO:3152
|
$207.07 Million |
|
QORIA Ltd
AU:QOR
|
$207.06 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Atrium Therapeutics, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,424,959,000 to 1,688,600,000, a change of 263,641,000 (18.5%).
- Net loss of 684,631,000 reduced equity.
- Other comprehensive income decreased equity by 340,000.
- Other factors increased equity by 948,612,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-684.63 Million | -40.54% |
| Other Comprehensive Income | $-340.00K | -0.02% |
| Other Changes | $948.61 Million | +56.18% |
| Total Change | $- | 18.50% |
Book Value vs Market Value Analysis
This analysis compares Atrium Therapeutics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.12x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-1.99 | $13.77 | x |
| 2019-12-31 | $-1.74 | $13.77 | x |
| 2020-12-31 | $14.14 | $13.77 | x |
| 2021-12-31 | $9.21 | $13.77 | x |
| 2022-12-31 | $11.08 | $13.77 | x |
| 2023-12-31 | $6.86 | $13.77 | x |
| 2024-12-31 | $12.77 | $13.77 | x |
| 2025-12-31 | $12.26 | $13.77 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Atrium Therapeutics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -40.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3650.39%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.16x
- Recent ROE (-40.54%) is below the historical average (-22.49%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -3148.81% | 0.10x | 0.00x | $-7.82 Million |
| 2019 | 0.00% | -1066.58% | 0.02x | 0.00x | $-18.20 Million |
| 2020 | -14.36% | -648.03% | 0.02x | 1.09x | $-74.60 Million |
| 2021 | -30.77% | -1258.52% | 0.02x | 1.12x | $-155.51 Million |
| 2022 | -29.25% | -1833.01% | 0.01x | 1.11x | $-226.88 Million |
| 2023 | -42.38% | -2219.87% | 0.02x | 1.26x | $-262.30 Million |
| 2024 | -22.62% | -2957.71% | 0.01x | 1.10x | $-464.80 Million |
| 2025 | -40.54% | -3650.39% | 0.01x | 1.16x | $-853.49 Million |
Industry Comparison
This section compares Atrium Therapeutics, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Atrium Therapeutics, Inc. Common Stock (RNA) | $1.69 Billion | 0.00% | 0.16x | $207.28 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |